Patient & Caregiver Annual Forum: Speakers

BACK TO FORUM DETAILS & REGISTRATION

 

Peter Black
DR. PETER BLACK,
 MD, FRCSC

Dr. Peter Black is a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and an Professor in the Department of Urologic Sciences at the University of British Columbia (UBC).

He has a clinical subspecialty interest in bladder cancer and also a translational research program in urothelial carcinoma. This research focuses on the integration of advanced biomarkers and novel targeted therapies to promote precision oncology and is supported by peer-reviewed grant funding. Dr. Black is also the Vice-Chair of the Bladder Cancer Canada Medical Research Board.

Dr. Anil Kapoor
DR. ANIL KAPOOR, MD, FRCSC

A leading uro-oncologist, Dr. Anil Kapoor is the current head of the Genito-Urinary program at the Juravinski Cancer Centre, Program Director of the McMaster University Residency Program and Surgical Director of the St. Joseph’s Hospital Transplant Program. A prominent Canadian researcher, he is advancing kidney cancer treatment by providing real-world evidence on the effectiveness of new drugs and combination therapies. He is extensively published and is the current Co-Chair of the NCIC Kidney Cancer Disease Group. He also plays a leadership role in The Kidney Cancer Research Network of Canada and recently served as Chair of Kidney Cancer Canada’s Medical Advisory Board. Dr. Kapoor is also a member of Kidney Cancer Canada’s Board of Directors.

Dr . Christian Kollmannsberger LONG
DR. CHRISTIAN KOLLMANNSBERGER, MD, FRCPC

Dr. Christian Kollmannsberger is staff medical oncologist at the British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre, and Clinical Professor at the University of British Columbia. Dr. Kollmannsberger trained in Germany before joining the BC Cancer Agency and University of British Columbia in 2004. 

His research focuses on genito-urinary malignancies with a special interest in testicular and renal cell cancer. This includes phase I, II and III clinical trials, the development of new therapeutic options and investigation of mechanisms of treatment resistance. 


BACK TO FORUM DETAILS & REGISTRATION